



## **GW Pharmaceuticals to Present at Upcoming Investor Conferences**

October 31, 2019

CARLSBAD, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Stephen Schultz, GW's Vice President of Investor Relations, will present at two upcoming conferences:

- the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day, on Monday, November 18th, 2019 at 10:30 a.m. EST
- the Stifel 2019 Healthcare Conference on Wednesday, November 20, 2019 at 1:15 p.m. EST

A live audio webcast of the presentations will be available through GW's corporate website at [www.gwpharm.com](http://www.gwpharm.com) on the Investors section under Events & Presentations. A replay will be available for each soon after the live presentation.

### **About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.**

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW's lead product, EPIDIOLEX (cannabidiol) oral solution is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. This product has received approval in Europe under the tradename EPIDYOLEX and is initially being commercialized in the 5 EU major markets. The Company continues to evaluate EPIDIOLEX in additional rare conditions including Tuberous Sclerosis Complex (TSC) and Rett syndrome. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the Company is now advancing a late stage program in order to seek FDA approval. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, autism, glioblastoma, and schizophrenia. For further information, please visit [www.gwpharm.com](http://www.gwpharm.com).

### **Enquiries:**

#### **GW Pharmaceuticals plc**

Stephen Schultz, VP Investor Relations 917 280 2424 / 401 500 6570  
(U.S.)